Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: A prospective study

Arthritis Care and Research

Volumn 55, Issue 5, 2006, Pages 786-790

  Perez Ruiz, Fernando ^a   Atxotegi, Joana ^a   Hernando, Iñaki ^a   Calabozo, Marcelo ^a   Nolla, Joan M ^b  

^a HOSPITAL DE CRUCES   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Gout; Gout suppressants; Withdrawal

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; BENZBROMARONE; URATE;

ADULT; AGED; ARTICLE; DRUG WITHDRAWAL; GOUT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; SURVIVAL; SYNOVIAL FLUID; TREATMENT DURATION; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; ARTHRITIS, GOUTY; BENZBROMARONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GOUT SUPPRESSANTS; HUMANS; LIFE STYLE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; TIME FACTORS; URIC ACID;

EID: 33750302478     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.22232     Document Type: Article

References (20)

1. Yu T, Yu TF. Milestones in the treatment of gout. Am J Med 1974;56:676-85.
2. Yu TF, Gutman AB. Principles of current management of primary gout. Am J Med Sci 1967;254:893-907.
3. Scott JT, Holloway VP, Glass HI, Arnot RN. Studies of uric acid pool size and turnover rate. Ann Rheum Dis 1969;28:366-73.
4. Edwards NL, Recker D, Airozo D, Fox IH. Enhanced purine salvage during allopurinol therapy: an important pharmacologic property in humans. J Lab Clin Med 1981;98:673-83.
5. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5.
6. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999;5:49-55.
7. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47:356-60.
8. Pascual E, Batlle-Gualda E, Martinez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999;131:756-9.
9. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-80.
10. Wortmann RL, Kelley WN. Gout and hyperuricemia. In: Harris ED Jr, editor. Kelley's textbook of rheumatology. 7th ed. Philadelphia: Elsevier Saunders; 2005. p. 1402-29.
11. Loebl WY, Scott JT. Withdrawal of allopurinol in patients with gout. Ann Rheum Dis 1974;33:304-7.
12. Gast LF. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. Clin Rheumatol 1987;6:70-3.
13. Van Lieshout-Zuidema MF, Breedveld FC. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993;20:1383-5.
14. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575-81.
15. Darmawan J, Rasker JJ, Nuralim H. The effect of control and self-medication of chronic gout in a developing country: outcome after 10 years. J Rheumatol 2003;30:2437-43.
16. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6.
17. Pascual E. Gout update: from lab to the clinic and back. Curr Opin Rheumatol 2000;12:213-8.
18. Benedict JD, Forsham PH, Stetten D Jr. The metabolism of uric acid in the normal and gouty human studied with the aid of isotopic uric acid. J Biol Chem 1949;181:183-93.
19. Bishop C, Garner W, Talbott JH. Pool size, turnover rate, and rapidity of equilibration of injected isotopic uric acid in normal and pathological subjects. J Clin Invest 1951;30:879-88.
20. Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;17:341-5.